Company
ImmuPharma PLC
LON:IMM
ImmuPharma PLC is a biopharmaceutical company that specializes in the usage and development of biopolymers, specifically peptides. The company is dedicated to developing an innovative portfolio of peptide-based therapeutic drugs with a focus on autoimmunity/inflammation and anti-infectives.
306 stories · page 12 of 16
Archive
Proactive news round-up: Kibo Mining, SDX Energy, Eland OIl...
A summary of some of the small cap stories on the Proactive newswire
Satellite group Inmarsat rockets on takeover speculation
Some of the main risers and fallers in London at 3.45pm...
ImmuPharma says lead lupus drug development programme on track to deliver results in the first quarter of 2017
Lupuzor, for the autoimmune disease lupus, is undergoing phase III clinical trials.
FTSE 100 closes higher; Paddy Power Betfair takes podium
After a gloomy morning for the pound, it started to build some momentum. FTSE 100 finished at 7,543
Archive
High Court to hear whether RBS rights issue case should proceed to trial
Day ahead: RBS likely to avert High Court trial; finals from FirstGroup, Johnson Matthey and ImmuPharma
Archive
Fourth-quarter improvement hoped for from IG Group
Week ahead; IG Group, Ryanair, Johnson Matthey, Non-Farm Payrolls,
Archive
Proactive news round-up: Nasstar, Redx Pharma, Keywords Studios...
A glance at some of the stories on the Proactive newswire...
BP ticks higher as shareholders back CEO's reduced pay at AGM
A look at some of the biggest London-listed risers and fallers today
ImmuPharma says Lupuzor trial in 'new territory' and on schedule
The trial runs for twelve months and 28 patients have now received the full dosage and 166 (80%) six months' worth
FTSE 100 closes lower as Trump fears grow; Dow Jones crashes
The UK blue chip index closed down 18.56 points at 7,503
Legal & General ups stake in ImmuPharma
L&G upped its stake in the recent £4.1mln fundraising, and now holds a 3.5% stake in ImmuPharma
Advanced Oncotherapy rallies on funding update
Some of the largest rises and falls in London at 10.00am: SynairGen, BOS Global, Angus Energy
Drug developer ImmuPharma raises £4.1mln in oversubscribed placing
The life sciences group said the accelerated book-build offering saw around 7.884 mln new shares placed at 52p each, a modest discount to last night’s closing share price
FTSE 100 ends higher as BT declares Openreach plans, US jobs gain
FTSE 100 stocks ended higher on Friday, led by telecoms behemoth BT after confirming it would separate Openreach